Oxford, UK – 5 January 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, announces that Dan Soland has been required to step down as a Non-Executive Director, due to his appointment as CEO of uniQure with immediate effect.
Commenting on the announcement, Dan Soland, said: “It is with regret that I have to step down as a Board member of Oxford BioMedica as a result of my appointment as CEO of uniQure. Oxford BioMedica has an outstanding position as a world-leader in gene and cell-therapy. The Company has an excellent business model well balanced by an exciting pipeline of wholly owned products, sought-after IP and third party manufacturing and process development. With its strong management team, I have no doubt that Oxford BioMedica is en route to long-term success and I have greatly enjoyed working with the team. I step down from my role feeling I leave the Company in an extremely strong position.”
Oxford BioMedica’s Chairman*, Nick Rodgers, said: “Dan has made a valuable contribution to Oxford BioMedica. We thank him for his input and wish him well for the future.”
*Oxford BioMedica announced on 15 December 2015 that Lorenzo Tallarigo (experience includes: Intercept Pharmaceuticals, Genextra and Eli Lilly) has been appointed as Non-Executive Chairman of the Group and will join on 1 February 2016.